Author:
Tojjari Alireza,Park Robin,Yu James,Saeed Anwaar
Publisher
Springer Science and Business Media LLC
Subject
Gastroenterology,General Medicine
Reference60 articles.
1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49. https://doi.org/10.3322/caac.21660.
2. Ajani JA, D’Amico TA, Bentrem DJ, Chao J, Cooke D, Corvera C, et al. Gastric cancer, version 2.2022, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw. 2022;20(2):167–92.
3. Folkman J. Tumor angiogenesis: Therapeutic implications. N Engl J Med. 1971;285(21):1182–6.
4. •• Wilke H, Muro K, Van Cutsem E, Oh S-C, Bodoky G, Shimada Y, et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): A double-blind, randomised phase 3 trial. Lancet Oncol. 2014;15(11):1224–35. This trial is pivotal in demonstrating the enhanced efficacy of combining ramucirumab with paclitaxel for treating advanced gastric or gastro-oesophageal junction adenocarcinoma, particularly in patients who have previously undergone treatment. It offers a new therapeutic avenue improving survival and quality of life in this patient population.
5. •• Fuchs CS, Tomasek J, Yong CJ, Dumitru F, Passalacqua R, Goswami C, et al. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): An international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2014;383(9911):31–9. This study is significant as it explored the use of ramucirumab as a standalone treatment for advanced gastric or gastro-oesophageal junction adenocarcinoma. Its findings contribute to understanding the potential of VEGFR2 targeted therapies in treating these cancers.